Weave Bio has secured $10 million in funding to accelerate its mission of streamlining regulatory processes for pharma and biotech. Its AI-powered platform, starting with AutoIND, automates and accelerates the IND submission process, reducing preparation time by over 50% and potentially bringing new therapies to patients faster while lowering development costs.

‍